Published in Ann Transl Med on December 01, 2015
Clinical Trial of Simvastatin to Treat Generalized Vitiligo | NCT01517893
Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86
Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76
Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol (2017) 0.75
Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin (2017) 0.75
The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol (2017) 0.75
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med (2013) 7.34
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med (2014) 1.82
Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov (2008) 1.64
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol (2015) 1.42
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2011) 1.32
Vitiligo. Lancet (2015) 1.27
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol (2015) 1.20
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Treatment of generalized vitiligo with anti-TNF-α Agents. J Drugs Dermatol (2012) 1.08
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut (2013) 1.05
Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol (2011) 1.04
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol (2014) 1.03
Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol (2010) 1.02
A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol (2012) 1.02
Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol (1977) 1.00
Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol (2006) 1.00
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol (2015) 1.00
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis (2004) 0.99
Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol (2004) 0.97
Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg (2011) 0.90
Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res (2014) 0.88
Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol (2014) 0.82
Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol (2011) 0.81
Why treatments do(n't) work in vitiligo: An autoinflammatory perspective. Autoimmun Rev (2014) 0.81
Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol (2011) 0.81
Vitiligo and alopecia areata: apples and oranges? Exp Dermatol (2013) 0.79
Etanercept in the treatment of vitiligo. Dermatology (2007) 0.78
Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin (2015) 0.77
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50